Summary of Research Findings

More documents

Recommendations

Info

Research on Reduction of Chemotherapy Toxicity (continued) Summary Use of the chemotherapeutic agent Adriamycin is complicated by its potentially lethal cardiac toxicity. DNA base pair damage induced by Adriamycin results in its effectiveness against cancer; however, simultaneous production of free radicals results in toxic side effects. In this study on mice, Adriamycin-induced mortality reached 60% in the control group (regular chow diet), compared to 20% in the group receiving a 6% MAK- 4-supplemented diet (p
Research on Reduction of Chemotherapy Toxicity (continued) therapy and 68 received chemotherapy alone and served as controls. There were two chemotherapy protocols used: cyclophosphamide plus adriamycin plus 5-fluorouracil (33 MAK patients and 32 control patients); and cyclophosphamide plus methotrexate plus 5-fluorouracil (28 MAK patients and 36 control patients). Patients received six cycles of chemotherapy at 28-day intervals and received ondansetron as an anti-emetic agent. Patients were evaluated for toxic side effects per World Health Organization (WHO) criteria. The mean age of the MAK patients and controls was similar: 43 ± 10 for the MAK group and 46 ± 9 for the controls. Results of the study showed improvement in several parameters for patients taking MAK as compared to controls: Karnofsky performance status, anorexia, vomiting, general well-being, and body weight. For the sixth cycle of chemotherapy, 27% more MAK patients had healthy Karnofsky scores, a scale that measures the ability to perform normal day-to-day activities. The overall average was 17.5% higher for MAK patients. For the fourth cycle of chemotherapy, 34% fewer MAK patients experienced loss of appetite (anorexia). The overall average was 26% less for patients taking MAK. For the third cycle of chemotherapy, 29% fewer MAK patients experienced vomiting. The overall average was 22% less for MAK patients. Also in the third cycle, 25% more MAK patients had a ‘good’ status of general well-being, with the overall average being 12% higher for MAK patients compared to controls. There was a statistically insignificant mean weight gain of 0.43 kg in the MAK patients, in comparison to a statistically significant mean weight loss of 1.12 kg in the control patients. Thus, patients on MAK were able to maintain their weight during treatment. Another important finding in this study was that there was no significant difference in tumor regression between the MAK patients and the controls. The MAK group had a statistically insignificant increase in the number of patients with tumor regression. This indicates that MAK does not impede the anti-cancer effects of chemotherapy. Thus, MAK is effective in reducing toxicity of chemotherapy treatment without impairing the anti-cancer effects of the chemotherapy. Percentage of Anorexia Anorexia Loss of appetite 27% 75% 27% 41% baseline 4th cycle baseline 4th cycle For the 4th cycle of chemotherapy 34% fewer Amrit patients experienced anorexia. The overall average was 26% less for Amrit patients. Amrit control Percentage of Good Status General Well-Being 64% 15% 40% 40% Amrit control baseline 3rd cycle baseline 3rd cycle For the 3rd cycle of chemotherapy 25% more Amrit patients had a “good” status. The overall average was 12% higher for Amrit patients. 16
Page 1 and 2: Summary of Research Findings Cancer
Page 3 and 4: Introduction.. . . . . . . . . . .
Page 5 and 6: Research on Anti-Aging, Neurophysio
Page 7 and 8: Introduction (continued) The effect
Page 9 and 10: Cancer Research (continued) 2. Titl
Page 11 and 12: Cancer Research (continued) Conduct
Page 13 and 14: Cancer Research (continued) Authors
Page 15: Research on Reduction of Chemothera
Page 19 and 20: Research on Reduction of Chemical T
Page 21 and 22: Research on Reduction of Chemical T
Page 23 and 24: Antioxidant Research (continued) MA
Page 25 and 26: Antioxidant Research (continued) Ab
Page 27 and 28: Antioxidant Research (continued) 6.
Page 29 and 30: Antioxidant Research (continued) 8.
Page 31 and 32: Antioxidant Research (continued) 10
Page 33 and 34: Antioxidant Research (continued) Su
Page 37 and 38: Antioxidant Research (continued) Ab
Page 39 and 40: Antioxidant Research (continued) Su
Page 45 and 46: Cardiovascular Research 1. Title Ef
Page 47 and 48: Cardiovascular Research (continued)
Page 57 and 58: Diabetes Research (continued) 56
Page 59 and 60: Immunity Research 1. Title Dose-Dep
Page 61 and 62: Immunity Research (continued) 2. Ti
Page 63 and 64: Immunity Research (continued) days.
Page 65 and 66: Immunity Research (continued) Study
Page 67 and 68:
Research on Anti-Aging, Neurophysio
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
1. Title Nutritional Insights From
Page 77 and 78:
Research on Chronic Diseases (conti
Page 79 and 80:
Research on Physiological Effects (
Page 81 and 82:
Research on the Maharishi Rejuvenat
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Research on the Transcendental Medi
Page 91 and 92:
Research on the Transcendental Medi
Page 93 and 94:
Bibliography 1. Sharma, H. and Clar
Page 95 and 96:
4. Student Rasayana: Centella asiat
Page 97 and 98:
NEW ZEALAND - NORWAY - RUSSIA - MAH
show all

Summary of Research Findings

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?